137 related articles for article (PubMed ID: 21639)
1. Hydroxylation of 5,5-diphenylhydantoin (phenytoin) by dog liver microsomes.
Butler TC; Dudley KH; Mitchell GN; Johnson D
Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):4-9. PubMed ID: 21639
[TBL] [Abstract][Full Text] [Related]
2. Studies of the metabolism of 5,5-diphenylhydantoin relating principally to the stereoselectivity of the hydroxylation reactions in man and the dog.
Butler TC; Dudley KH; Johnson D; Roberts SB
J Pharmacol Exp Ther; 1976 Oct; 199(1):82-92. PubMed ID: 978486
[TBL] [Abstract][Full Text] [Related]
3. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
Yamazaki H; Komatsu T; Takemoto K; Saeki M; Minami Y; Kawaguchi Y; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):427-34. PubMed ID: 11259327
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
Munns AJ; De Voss JJ; Hooper WD; Dickinson RG; Gillam EM
Chem Res Toxicol; 1997 Sep; 10(9):1049-58. PubMed ID: 9305589
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
Billings RE
J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
[TBL] [Abstract][Full Text] [Related]
6. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man.
Claesen M; Moustafa MA; Adline J; Vandervorst D; Poupaert JH
Drug Metab Dispos; 1982; 10(6):667-71. PubMed ID: 6130920
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective inhibition of diphenylhydantoin metabolism by p-hydroxyphenyl-phenylhydantoin enantiomers in rats.
Huang JD; Hsieh CY
Chirality; 1991; 3(6):454-9. PubMed ID: 1812955
[TBL] [Abstract][Full Text] [Related]
8. Kinetic and spectral studies of type I and type II compounds with rat hepatic microsomes in the presence of the major metabolite of diphenylhydantoin.
Stavchansky SA; Kostenbauder HB; Lubawy WC
Drug Metab Dispos; 1975; 3(6):557-64. PubMed ID: 1233
[TBL] [Abstract][Full Text] [Related]
9. Phenytoin metabolism in mice.
Chow SA; Fischer LJ
Drug Metab Dispos; 1982; 10(2):156-60. PubMed ID: 6124402
[TBL] [Abstract][Full Text] [Related]
10. Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
Kamali F; Ball DE; McLaughlin WS; Seymour RA
J Periodontal Res; 1999 Apr; 34(3):145-53. PubMed ID: 10384402
[TBL] [Abstract][Full Text] [Related]
11. Absolute configuration of (+)-5-(o-hydroxyphenyl)-5-phenylhydantoin, the major metabolite of 5,5-diphenylhydantoin in the dog.
Maguire JH; Butler TC; Dudley KH
J Med Chem; 1978 Dec; 21(12):1294-7. PubMed ID: 722736
[TBL] [Abstract][Full Text] [Related]
12. Evidence for an arene-3,4-oxide as a metabolic intermediate in the meta- and para-hydroxylation of phenytoin in the dog.
Moustafa MA; Claesen M; Adline J; Vandervorst D; Poupaert JH
Drug Metab Dispos; 1983; 11(6):574-80. PubMed ID: 6140142
[TBL] [Abstract][Full Text] [Related]
13. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
[TBL] [Abstract][Full Text] [Related]
14. Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins.
Pantarotto C; Arboix M; Sezzano P; Abbruzzi R
Biochem Pharmacol; 1982 Apr; 31(8):1501-7. PubMed ID: 7092941
[TBL] [Abstract][Full Text] [Related]
15. Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin.
Ohnmacht CM; Chen S; Tong Z; Hage DS
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 836(1-2):83-91. PubMed ID: 16621742
[TBL] [Abstract][Full Text] [Related]
16. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
O'Leary TD; Sansom LN
J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid-induced inhibition in the biotransformation of [14C] diphenylhydantoin in rat.
Buttar HS
Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):35-57. PubMed ID: 905633
[TBL] [Abstract][Full Text] [Related]
18. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous determination of p-hydroxylated and dihydrodiol metabolites of phenytoin in urine by high-performance liquid chromatography.
Szabo GK; Pylilo RJ; Davoudi H; Browne TR
J Chromatogr; 1990 Dec; 535(1-2):279-85. PubMed ID: 2089057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
